Biocon Ltd will set up its first overseas manufacturing and research facility in Malaysia with an initial investment of around Rs 715 crore ($ 160 mn) .The USFDA-compliant plants would be operational by 2014 and make high-end biosimilars and biopharmaceuticals for the global market. It is said to be the biggest biotechnology investment in Malaysia. A large amount (of the present investment) would come from Pfizer's upfront payments ($200 million) and internal accruals. We also got good incentives from the Malaysian government.
In the next phase, Biocon would utilise the facility for production of anti-bodies and other biologics. The facility would also generate employment for close to 500 people in total, starting with 250 to 300 people in phase I. The investment follows a memorandum of agreement signed earlier this year between Biocon and BiotechCorp to manufacture bio-pharmaceutical products and formulations, enable the transfer of knowledge to Malaysia's human capital, and create employment.